This article focuses on the conditional approvals issued by the Chinese antitrust authority in 2018 involving Bayer/Monsanto, Essilor/Luxottica, Linde/ Praxair, and UTC/Rockwell Collins. This article analyses these four cases from both the procedural and substantive perspectives. We conclude that, in terms of procedure, one of the most significant features may be the long period of time review may take. From the substantive perspective, the authority tends to adopt tailor-made behavioral remedies to address its particular concerns. Remarks are also made regarding the general practice of merger remedies in China.